Souverijns Wim sold $1.0M of PHVS

Souverijns Wim (Chief Commercial Officer) sold 26,090 shares of Pharvaris N.V. (PHVS) at an average of $39.23 ($38.99–$39.31, $1.02M total) across 2 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Souverijns Wim
Published Sep 16, 2026, 6:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The sale reduces insider ownership and may be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.

02

Market read

Insider sales are closely watched for signals; a $1M C‑level sale in a micro‑cap biotech is noteworthy for traders.

03

Timing

filed today

Relevance 5/10Novelty 6/10Timing: filed today

Background

SEC Form 4 filing discloses an insider sale by the company's Chief Commercial Officer.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Chief Commercial Officer sold 26,090 shares for $1.02M via a 10b5‑1 plan, reducing his stake to 39,021 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

C‑level insider selling $1M is material for a small‑cap biotech, but the amount is not large enough to trigger a sharp move.

Key entities

  • Pharvaris N.V.

    Biotech company listed on Nasdaq under ticker PHVS.

  • Souverijns Wim

    Chief Commercial Officer of Pharvaris who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.